Adult-onset Still's disease

Lore & Background

Treatment includes anti-inflammatory medications, with steroids such as prednisone used for severe symptoms. Newer medications target interleukin-1, particularly IL-1β. In June 2020, the FDA approved Ilaris (canakinumab) for AOSD, the first FDA-approved treatment for the condition. Other options include anakinra, rilonacept, and the monoclonal anti-IL6 antibody tocilizumab. Obvious similarities exist with juvenile rheumatoid arthritis, and there is some evidence that the two conditions are closely related.

Reader's Guide

Adult-onset Still's disease is significant as a rare systemic autoinflammatory disorder that can cause severe life-threatening complications affecting the lungs, heart, or kidneys, as well as hemophagocytic lymphohistiocytosis, fulminant hepatitis, and disabling conditions such as aseptic meningitis and sensorineural hearing loss. Its prognosis is usually favorable, but the disease requires careful diagnosis of exclusion to rule out other inflammatory and autoimmune diseases. The development of targeted therapies blocking interleukin-1, particularly the FDA approval of canakinumab in 2020, marked a milestone in treatment. The disease's link to juvenile-onset Still's disease (now grouped under juvenile rheumatoid arthritis) suggests a shared pathophysiology. Research continues into using calprotectin levels for improved diagnosis and monitoring. The condition was first characterized in adults by E. G. Bywaters in 1971, building on the work of Sir George Frederic Still, for whom the disease is named.

Did You Know?

• The disease is named after English physician Sir George Frederic Still (1868–1941).
• Levels of the iron-binding protein ferritin may be extremely elevated in AOSD.
• The FDA approved canakinumab (Ilaris) for AOSD in June 2020, the first FDA-approved treatment for the condition.
• Onset is most common in two age ranges: between ages 16–25 and between ages 36–46.

The Diagnostic Maze: Recognizing a Rare Inflammatory Condition

Adult-onset Still's disease presents one of rheumatology's most challenging puzzles. The hallmark triad—high fevers, joint pain, and a distinctive salmon-pink macular or maculopapular rash—often overlaps with other inflammatory and autoimmune disorders, making AOSD fundamentally a diagnosis of exclusion. Clinicians must rule out competing conditions before committing to this label. Bloodwork typically reveals a strikingly elevated ferritin level alongside a neutrophil-predominant white blood cell count, while rheumatoid factor and anti-nuclear antibody tests usually come back negative. Additional hallmarks include hepatosplenomegaly, lymphadenopathy, and during flares, profound fatigue and occasionally pleural or pericardial effusions. Because no single serological marker confirms the disease, diagnosis remains clinical. At least seven sets of criteria have been proposed over the years, but the Yamaguchi criteria carry the highest sensitivity, requiring a minimum of five features including at least two major ones. Patients generally follow one of two trajectories: a debilitating systemic course with fevers and multi-organ involvement, or a less aggressive pattern dominated by chronic arthritis.

From Steroids to Targeted Biologics: The Treatment Frontier

Managing adult-onset Still's disease has evolved considerably. Corticosteroids, particularly prednisone, remain the first-line intervention for severe symptomatic episodes. When standard steroid regimens fail to control the disease, a broader arsenal of immunosuppressive agents—including methotrexate, azathioprine, hydroxychloroquine, penicillamine, cyclophosphamide, and several biologic agents such as etanercept, adalimumab, infliximab, and rituximab—may be deployed, though these are used less frequently. A pivotal shift arrived with interleukin-1–targeting therapies. Anakinra, which blocks IL-1 action, demonstrated superior outcomes in a randomized multicenter trial comparing twelve treated patients against ten on conventional disease-modifying antirheumatic drugs. In June 2020, the FDA granted approval to canakinumab (marketed as Ilaris), marking the first-ever FDA-approved treatment specifically for AOSD. Canakinumab selectively binds IL-1β, while rilonacept blocks both IL-1α and IL-1β. Tocilizumab, a monoclonal antibody against IL-6, has also shown efficacy comparable to anakinra, broadening the therapeutic toolkit for patients who do not respond to earlier options.

Prognosis, Complications, and Disease Patterns

For most individuals, the outlook with adult-onset Still's disease is reassuring, with a generally favorable long-term prognosis. However, when the inflammatory process extends to the lungs, heart, or kidneys, the situation can deteriorate into life-threatening territory. Rare but devastating complications documented in the literature include hemophagocytic lymphohistiocytosis, fulminant hepatitis, intervertebral disc calcification, aseptic meningitis, and sensorineural hearing loss. Hematological complications such as thrombotic microangiopathy, though more commonly linked to rheumatoid arthritis, have also been reported in Still's disease. The clinical course tends to fall into recognizable patterns. In one classification of twenty-one patients, four distinct trajectories emerged: monocyclic systemic disease, polycyclic systemic disease, chronic articular monocyclic systemic disease, and chronic articular polycyclic systemic disease. Those whose disease manifests as chronic articular or polyarticular involvement face a meaningfully higher risk of developing disabling arthritis, underscoring why early recognition of the pattern matters for long-term joint preservation.

Origins, Rarity, and the Search for Better Markers

The condition carries the name of Sir George Frederic Still, an English physician who lived from 1868 to 1941 and first described the juvenile form. The adult-onset variant was formally characterized by E. G. Bywaters in 1971, distinguishing it from what is now typically grouped under juvenile rheumatoid arthritis, though the two conditions share obvious clinical similarities and some evidence suggests a close biological relationship. AOSD is genuinely rare worldwide, with an estimated incidence of roughly 1.6 new cases per million people each year and a prevalence of about 1.5 per 100,000 to 1,000,000. Onset clusters in two distinct age windows: between sixteen and twenty-five, and between thirty-six and forty-six. The underlying cause remains unknown, and the disease is not heritable, yet the therapeutic success of IL-1–blocking agents strongly implicates interleukin-1 in its pathophysiology, with interleukin-18 also expressed at elevated levels. Current research is exploring whether calprotectin levels might serve as a practical tool for refining diagnosis and tracking disease activity over time.